Table 4.
Hypertension and Proteinuria in ARPKD Subjects and Controls
| Characteristic | ARPKD Subjects (n=22) | A/H/D Controls (n=44) | p-value | OU Controls (n=44) | p-value |
|---|---|---|---|---|---|
| Baseline (casual) systolic blood pressure (SBP) percentilea | 83 [44,97] | 68 [31,94] | 0.31 | 72 [60,89] | 0.56 |
| Casual hypertensionb, | 7 (32%) | 9 (20%) | 0.37 | 6 (14%) | 0.10 |
| Ambulatory hypertensionc | 6/12 (50%) | 8/22 (36%) | 0.49 | 20/28 (71%) | 0.28 |
| LVHb,c | 4 (20%) | 4 (10%) | 0.42 | 2 (6%) | 0.19 |
| Anti-hypertensive medication useb | 19 (86%) | 18 (41%) | 0.0004 | 15 (34%) | 0.0001 |
| ACEIsb | 18 (82%) | 16 (36%) | 0.0004 | 12 (27%) | <0.0001 |
| ARBsb | 2 (9%) | 0 (0%) | 0.11 | 2 (5%) | 0.60 |
| # of Anti-hypertensives | |||||
| 0 | 3 (14%) | 26 (59%) | <0.0001 | 29 (66%) | <0.0001 |
| 1-2 | 12 (55%) | 18 (41%) | 15 (35%) | ||
| ≥3 | 7 (32%) | 0 (0%) | 0 (0%) | ||
| Urine protein: Creatinine ratio (mg/mg)a | 0.1 [0.1,0.2] | 0.6 [0.1,1.5] | 0.003 | 0.6 [0.2,0.9] | 0.0001 |
| Urine protein: creatinine > 0.2 (mg/mg)b | 6 (27%) | 28 (68%) | 0.003 | 33 (77%) | 0.0002 |
a
Median [interquartile range]
b
Number (percent)
c
Number positive/number studied (percent). Significant p values (p<0.05) are shown in bold ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; LVH, left ventricular hypertrophy